Abstract
Mosapride is novel prokinetic agent which seems to exert its action via a high affinity and specifity for 5-HT 4 receptor. In addition the principal metabolite has high affinity for 5-HT 3 receptors and has proved to be potent 5-HT 3 antagonist. Mosapride has been used to treat gastroesophageal reflux disease, chronic gastritis, nonulcer dyspepsia and diabetic gastropathy. In the present study, an attempt has been made to formulate orodispersible tablets of Mosapride Citrate Dihydrate. The other objective of the study was to evaluate the performance of three different classes of superdisintegrants which are croscarmellose Sodium (Ac-Di-Sol), crospovidone (Polyplasdone XL), sodium starch glycolate (Primojel) in promoting disintegration and dissolution of Mosapride Citrate Dihydrate orodispersible tablets. At the optimum concentrations of 2% & 4% of selected superdisintegrants, their effect in the orodispersible tablet on the in vitro disintegration & in vitro dissolution was evaluated. It was concluded that, the formulation of Mosapride Citrate Dihydrate orodispersible tablets was made with functionality evaluation of selected superdisintegrants. KEYWORDS: Mosapride Citrate Dihydrate, Orodispersible tablets, Superdisintegrants, Crospovidone, Prokinetic agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Journal of Biomedical and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
